Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Inhibition of PI3K Alpha and PI3K Delta with Copanlisib Shows Preclinical Activity As a Single Agent and in Combination in Multiple Myeloma

Sarah M Larson, MD, Mao Yu Peng, PhD, Monica Mead, MD BS, Andrae Vandross, MD, Dylan Conklin, PhD, Erika Von Euw, PhD, Dennis J. Slamon, MD PhD

Blood (2017) 130 (Supplement 1): 3084.

https://doi.org/10.1182/blood.V130.Suppl_1.3084.3084

Published: 2017

Journal Articles

Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)

Neil P. Shah, MD PhD, Jose Valentín García Gutiérrez, PhD, Antonio Jiménez-Velasco, MD, Sarah M Larson, MD, Susanne Saussele, MD, Delphine Rea, MD, François-Xavier Mahon, MD PhD, Moshe Levy, MD, María Teresa Gómez-Casares, MD PhD, Fabrizio Pane, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Oumar Sy, PhD, Patricia Martin-Regueira, MD, Jeffrey H. Lipton, PhD MD FRCPC

Blood (2017) 130 (Supplement 1): 314.

https://doi.org/10.1182/blood.V130.Suppl_1.314.314

Published: 2017

Journal Articles

Outcomes of Classical Hodgkin Lymphoma in US Hematology Practices: Initial Data from a Prospective Real-World Study

Christopher A. Yasenchak, MD, Jakub Svoboda, MD, Sarah M Larson, MD, Don A Stevens, MD, Srikanth Gajavelli, MD, Trong Kim Le, Philippe Armand, MD PhD

Blood (2017) 130 (Supplement 1): 5626.

https://doi.org/10.1182/blood.V130.Suppl_1.5626.5626

Published: 2017

Journal Articles

Activity of the Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Copanlisib, As a Single Agent and in Combination with Carfilzomib in Multiple Myeloma

Sarah M Larson, MD, Mao Yu Peng, PhD, Andrae Vandross, MD, Monica Mead, MD BS, Zoe Fuchs, Dylan Conklin, PhD, Erika Von Euw, PhD BS, Dennis J. Slamon, MD PhD

Blood (2016) 128 (22): 5665.

https://doi.org/10.1182/blood.V128.22.5665.5665

Published: 2016

Journal Articles

Systematic Comparison of the EF-1 Alpha Short (EFS) and Viral Promoters for Gene Modification of Human Primary Cells for Clinical Applications

Roy L. Kao, MD, Eric H. Gschweng, BS, Avigael Rebecca Lerman, Sarah M. Larson, MD, Andy Tu, Tulika Tyagi, MS, Shantha Senadheera, MS, Roger P. Hollis, PhD, Satiro N. De Oliveira, MD

Blood (2014) 124 (21): 3497.

https://doi.org/10.1182/blood.V124.21.3497.3497

Published: 2014

Journal Articles

Second-Generation Chimeric Antigen Receptors Successfully Modify Hematopoietic Stem Cells for Immunotherapy of B-Lineage Malignancies

Roy L. Kao, MD, Tulika Tyagi, MS, Sarah M. Larson, MD, Andy Tu, Shantha Senadheera, MS, Roger P. Hollis, PhD, Satiro N. De Oliveira, MD

Blood (2014) 124 (21): 655.

https://doi.org/10.1182/blood.V124.21.655.655

Published: 2014

Journal Articles

Anti-CD19 Chimeric Antigen Receptor Controlled By The Suicide Gene HSVsr39TK In Hematopoietic Stem Cells For Immunotherapy Of B-Lineage Malignancies

Sarah M. Larson, MD, Andy Tu, Shanta Senadheera, Michelle Ho, BS, Donald B. Kohn, MD, Satiro deOliveira, MD

Blood (2013) 122 (21): 1659.

https://doi.org/10.1182/blood.V122.21.1659.1659

Published: 2013

NARROW

Inhibition of PI3K Alpha and PI3K Delta with Copanlisib Shows Preclinical Activity As a Single Agent and in Combination in Multiple Myeloma

Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)

Outcomes of Classical Hodgkin Lymphoma in US Hematology Practices: Initial Data from a Prospective Real-World Study

Activity of the Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Copanlisib, As a Single Agent and in Combination with Carfilzomib in Multiple Myeloma

Systematic Comparison of the EF-1 Alpha Short (EFS) and Viral Promoters for Gene Modification of Human Primary Cells for Clinical Applications

Second-Generation Chimeric Antigen Receptors Successfully Modify Hematopoietic Stem Cells for Immunotherapy of B-Lineage Malignancies

Anti-CD19 Chimeric Antigen Receptor Controlled By The Suicide Gene HSVsr39TK In Hematopoietic Stem Cells For Immunotherapy Of B-Lineage Malignancies

Email alerts

ASH Publications

American Society of Hematology

Inhibition of PI3K Alpha and PI3K Delta with Copanlisib Shows Preclinical Activity As a Single Agent and in Combination in Multiple Myeloma

Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)

Outcomes of Classical Hodgkin Lymphoma in US Hematology Practices: Initial Data from a Prospective Real-World Study

Activity of the Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Copanlisib, As a Single Agent and in Combination with Carfilzomib in Multiple Myeloma

Systematic Comparison of the EF-1 Alpha Short (EFS) and Viral Promoters for Gene Modification of Human Primary Cells for Clinical Applications

Second-Generation Chimeric Antigen Receptors Successfully Modify Hematopoietic Stem Cells for Immunotherapy of B-Lineage Malignancies

Anti-CD19 Chimeric Antigen Receptor Controlled By The Suicide Gene HSVsr39TK In Hematopoietic Stem Cells For Immunotherapy Of B-Lineage Malignancies

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only